Joinn Laboratories(China)Co (603127) fair value: what the stock is really worth
We calculate from audited financials what Joinn Laboratories(China)Co is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily, free.
Compare price with fair valuebelow fair value = cheap, above = expensive
Check the quality50 and up solid, 75 and up strong
Watch it or check another stockalert when fair value or trend changes
A solid business, but trading 362% above our fair value of ¥9.22.
As of Sep 5, 2026, the fair value of Joinn Laboratories(China)Co is ¥9.22 per share against a price of ¥42.57, so the fair value sits 78% below the price. A model estimate from reported figures, not an analyst target.
!Weak Growth (revenue 5y +9.0 %/yr)
✓Highly profitable · 29.4% net margin
✓Low debt · generates free cash flow
·0.28% dividend yield
!Trails peers (5/13)
!Narrow moat 39/100
!Evidence only medium, so the estimate is less certain
!Weak on past: 24 out of 100
!Weak on dividend: 6 out of 100
Evidence: MediumRange ¥7.24 to ¥9.63
Fair value as of: Sep 5, 2026
From 23 valuation models · updated 6 days ago
Share price −16.9% over the past month.
This is the short version. In the app for Joinn Laboratories(China)Co:
Watch Joinn Laboratories(China)Co for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceable See the method →
What matters now
The price sits above even our optimistic bull case (¥9.63). The favourable scenario is already priced in.
Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 5, 2026.
How to read this chart
60‑month range ¥12.46 – ¥87.11 · fair‑value band ¥7.24 – ¥9.63 · the ¥42.57 price screens above the ¥9.22 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 5, 2026.
Joinn Laboratories(China)Co (603127) currently trades at ¥42.57, while our model-based Fair Value estimate is ¥9.22, implying the stock looks roughly 361.7% overvalued today. The Quality Score stands at 60/100 (solid quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of ¥13.89 per share, and 0 of the 23 models we run sit above the ¥42.57 price. Bear case: the Multiples group reads lowest at ¥8.03, and 23 of the 23 models stay below the price. Evidence for this calculation is medium.
Over the trailing twelve months, Joinn Laboratories(China)Co generated revenue of 1.7B CNY at a net margin of 29.4%. Revenue grew 10.0% year over year. It earns a return on equity of 5.9%. The balance sheet holds a net cash position of 904M CNY. Fundamentals as of Sep 5, 2026
Scenario range: ¥7.24 (bear) to ¥9.63 (bull), the price of ¥42.57 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target. The share trades about 7% below its 52-week high and 130% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −50% fair-value upside, at −78%, 603127 screens richer than that median.
Fair Value models
Based on fiscal year 2025 figures (about 8 months old). Earnings retained since then (¥0.3827 per share) are deliberately not added.
Each model values the company its own way; the fair value above is the evidence-weighted blend. Evidence (0 to 100) shows how complete a model's inputs are. How we calculate →
Note: the current price implies far more future growth than the conservative anchors of our models allow (base growth is deliberately capped, we do not regard such extreme rates as sustainable). Our models are not designed for expectations this high; that is why the individual models scatter extremely (¥0.5700 to ¥22.41). Read the values as a conservative anchor, not as a price target.
ModelBear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence
Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
P/E ratio48.3as of Jun 15, 2026
P/S ratio8.68P/E × margin
EPS (TTM)¥0.6700price ÷ EPS = P/E 48.3
Dividend yield0.3%payout 17.9%
Net margin18.0%FY2025
Return on equity5.9%TTM
More key figures
Profitability
Return on assets (EBIT)5.1%avg 5y
Operating margin−9.7%TTM
Growth
Revenue (TTM)1.7B CNYTTM
Revenue growth (YoY)+10.0%3y avg −9.9%
EPS growth (YoY)+540%
Balance sheet & cash flow
Free cash flow301M CNYFY2025
Net cash904M CNYFY2024
Figures from reported company fundamentals · as of Sep 5, 2026. TTM = trailing twelve months.
Quality Score breakdown
Overall quality60/100
Of which business quality 60
· Market factors (momentum, volatility) 64
Profitability29
Margins and returns on capital today
Quality Growth20
Are margins and returns improving?
Cashflow72
Earnings quality: real cash, not paper profit
Fin. Strength83
Balance sheet, leverage, solvency risk
Investment87
Disciplined investing over empire-building
Low Volatility38
Calm price path (market factor)
Momentum82
Price trend over the last 3–12 months (market factor)
52W Momentum63
Distance to the 52-week high (market factor)
Net Issuance76
Buybacks instead of dilution
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models.
Full company description
Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics DMPK studies, and pharmacology and efficacy studies. Its Clinical Trial and Related Services segment provide clinical contract research organization services, co-managed phase I clinical research units, and bioanalytical services. The Sales of Research Models segment engages in the design, production, breeding, and sale of research models, including non-human primates and rodents. The company also offers cell-based assay (CBA) services. In addition, it offers drug quality research and testing services for protein drugs, vaccines, gene and cell therapy products, and provides customized solutions for early-stage drug discovery, screening, and mechanism research. Joinn Laboratories(China)Co.,Ltd. was incorporated in 1995 and is headquartered in Beijing, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Joinn Laboratories(China)Co reported revenue of 1.7B CNY in FY2025 versus 1.5B CNY in FY2021, a compound +2.2%/yr. Reported net income was 298M CNY in FY2025, compounding −14.5%/yr from FY2021.
Growth Quality 40/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
1.7B CNY
Latest YoY
−17.9%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−9.9%
Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+9.0%
Avg. revenue growth/yr (13Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+24.4%
Value creation/yr (5Y) ⓘEarnings growth per share (CAGR 5 years) plus dividend yield: value created per share and year.
−4.4%
Earnings growth per share plus dividend yield: the value created per share and year.
Earnings growth per share−4.7%
Dividend yield0.3%
Trend ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.5Y −4.7% vs 10Y 14.1%, flattening
Operating margin (EBIT) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.33.7% (2019) → −2.5% (2025) · falling
Worst earnings drop93% (2024) · in CNY
Revenue+2.2%/yr
FY211.5B CNY
FY222.3B CNY
FY232.4B CNY
FY242.0B CNY
FY251.7B CNY
Net income−14.5%/yr
FY21557M CNY
FY221.1B CNY
FY23397M CNY
FY2474.1M CNY
FY25298M CNY
Character of growth · EPS growth decomposed (2013-2024)+25.9 % p.a.
Revenue per share+25.5 %
of which total revenue +32.3 % · buybacks/dilution −5.2 %
EBIT margin+3.2 %
Tax rate+0.1 %
Residual (interest, one-offs)−2.9 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Joinn Laboratories(China)Co Fair Value". https://www.fairvalue-calculator.com/stock/603127
Peer Group
Diagnostics & Research · 133 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation
Quality Score60 · Above median
Fair Value upside−79% · Bottom 25%
Profitability
Return on equity (TTM)6% · Above median
Return on assets−1% · Below median
Net margin (TTM)29% · Top 25%
Operating margin (TTM)−10% · Below median
Growth and dividend
Revenue growth10% · Above median
Dividend yield (TTM)0.3% · Below median
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
P/E (TTM)48.3× · Pricier than median
P/B4.58× · Pricier than median
P/S (TTM)22.61× · Priciest 25%
P/FCF18.9× · Pricier than median
What the price implies (reverse DCF)
The inverse question: what free-cash-flow growth must Joinn Laboratories(China)Co deliver for ten years so that today's price is fair in our DCF model? Same formula, same discount rate as the fair value.
Implied FCF growth, 10 years+30.2 % per year
Achieved revenue growth, 5 years+9.0 % p.a.
Sector median revenue growth+4.4 %
FCF yield on price0.94 %
Discount rate (WACC) in the models9.9 %
The price demands an acceleration versus past growth: a high bar the company still has to clear. Ranking of the largest stocks →
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
This stockSector peers
VALUE0· sector 0
FUTURE50· sector 31
PAST24· sector 11
HEALTH100· sector 96
DIVIDEND6· sector 20
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Sep 5, 2026).
Is Joinn Laboratories(China)Co (603127) overvalued or undervalued?
As of Sep 5, 2026, our model estimates a fair value of ¥9.22 versus a price of ¥42.57, about −78% upside (overvalued).
What is the fair value of 603127?
Our model-based fair value for Joinn Laboratories(China)Co is ¥9.22 (as of Sep 5, 2026), built from audited fundamentals. The current price: ¥42.57.
What is the quality score of 603127?
Joinn Laboratories(China)Co has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Joinn Laboratories(China)Co (603127)?
Our model-based price target is the fair value of ¥9.22 (as of Sep 5, 2026) from 23 valuation models. Cautious scenario ¥7.24, optimistic scenario ¥9.63. It is a calculation from audited fundamentals, not an analyst target.
What is the Joinn Laboratories(China)Co stock forecast for 2026?
Our models put fair value at ¥9.22, about −78% upside versus a price of ¥42.57 (overvalued). Cautious scenario ¥7.24, optimistic scenario ¥9.63. The calculation is refreshed regularly with new filings.
What is the revenue of Joinn Laboratories(China)Co (603127)?
Joinn Laboratories(China)Co reported trailing-twelve-month revenue of about 1.7B CNY (latest available figure, as of Sep 5, 2026).
What is the net profit margin of 603127?
The net profit margin of Joinn Laboratories(China)Co is about 29.4%, meaning it keeps roughly 29.4% of revenue as net income. Based on the latest reported figures.
Does Joinn Laboratories(China)Co pay a dividend?
Joinn Laboratories(China)Co currently shows a dividend yield of about 0.28% relative to its recent price (as of Sep 5, 2026).
What growth is priced into Joinn Laboratories(China)Co (603127)?
For today's price to be fair in a discounted-cash-flow model, Joinn Laboratories(China)Co would have to grow free cash flow by +30.2 % per year for ten years (discount rate 9.9 %, then 2 % perpetual growth). Over the last 5 years revenue grew +9.0 % per year. As of Sep 5, 2026.
What discount rate (WACC) does the fair value of 603127 use?
Our models discount Joinn Laboratories(China)Co at 9.9 %: a base by market capitalisation (mid), damped by beta 0.81, country premium for China. The same rate applies in all 26 models.
What is the intrinsic value of Joinn Laboratories(China)Co (603127)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Joinn Laboratories(China)Co it is ¥9.22 per share (as of Sep 5, 2026), against a price of ¥42.57. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is Joinn Laboratories(China)Co stock overvalued or undervalued in 2026?
As of Sep 5, 2026, 603127 trades above its calculated fair value: price ¥42.57, fair value ¥9.22, a gap of about −78% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 603127?
No. The price is what the market pays today (¥42.57); the fair value is what the company's own numbers justify (¥9.22). For Joinn Laboratories(China)Co the two are ¥33.35 per share apart. That gap is exactly why we show both numbers side by side.
How much is Joinn Laboratories(China)Co worth?
The market values Joinn Laboratories(China)Co at about 38.1B CNY (market capitalisation, as of Sep 5, 2026). Per share that is ¥42.57; our models calculate a fair value of ¥9.22 per share.
What do the bullish and bearish scenarios say about 603127?
Our models span a range for Joinn Laboratories(China)Co: cautious scenario ¥7.24, base ¥9.22, optimistic ¥9.63 per share (as of Sep 5, 2026, price ¥42.57). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 603127?
Joinn Laboratories(China)Co trades at a price-to-earnings ratio of 48.3 (as of Sep 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥9.22 is built from several models across several years. Other multiples: P/B 4.6, P/S 22.6.
How solid is the balance sheet of Joinn Laboratories(China)Co (603127)?
Balance-sheet figures for Joinn Laboratories(China)Co (as of Sep 5, 2026): return on equity 5.9%. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is 603127 from its 52-week high?
Joinn Laboratories(China)Co trades at ¥42.57, about 7% below its 52-week high of ¥45.95 and 130% above the low of ¥18.50 (as of Sep 5, 2026). Distance from the high says nothing about value: that is what the fair value of ¥9.22 is for.
Which stocks are comparable to Joinn Laboratories(China)Co?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Joinn Laboratories(China)Co stock attractive at the current price?
The data as of Sep 5, 2026: price ¥42.57, calculated fair value ¥9.22 (−78%), Quality Score 60/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 603127 calculated?
We run Joinn Laboratories(China)Co through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥9.22, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 32.6 % above its aggregate fair value. Joinn Laboratories(China)Co itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on <a href="/is-it-worth-investing-now/">is it worth investing now</a>.
Free · no account needed
Watch Joinn Laboratories(China)Co in the live analysis
One click puts Joinn Laboratories(China)Co on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
